BRPI1010517A2 - métodos para prevenção e/ou tratamento de doenças de armazenamento lisossomal - Google Patents

métodos para prevenção e/ou tratamento de doenças de armazenamento lisossomal

Info

Publication number
BRPI1010517A2
BRPI1010517A2 BRPI1010517A BRPI1010517A BRPI1010517A2 BR PI1010517 A2 BRPI1010517 A2 BR PI1010517A2 BR PI1010517 A BRPI1010517 A BR PI1010517A BR PI1010517 A BRPI1010517 A BR PI1010517A BR PI1010517 A2 BRPI1010517 A2 BR PI1010517A2
Authority
BR
Brazil
Prior art keywords
prevention
treatment
methods
lysosomal storage
storage diseases
Prior art date
Application number
BRPI1010517A
Other languages
English (en)
Portuguese (pt)
Inventor
Lee Gary
Boyd Robert
Original Assignee
Amicus Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amicus Therapeutics Inc filed Critical Amicus Therapeutics Inc
Publication of BRPI1010517A2 publication Critical patent/BRPI1010517A2/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90Enzymes; Proenzymes
    • G01N2333/914Hydrolases (3)
    • G01N2333/924Hydrolases (3) acting on glycosyl compounds (3.2)

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BRPI1010517A 2009-04-09 2010-04-09 métodos para prevenção e/ou tratamento de doenças de armazenamento lisossomal BRPI1010517A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16810909P 2009-04-09 2009-04-09
PCT/US2010/030472 WO2010118283A1 (en) 2009-04-09 2010-04-09 Methods for preventing and/or treating lysosomal storage disorders

Publications (1)

Publication Number Publication Date
BRPI1010517A2 true BRPI1010517A2 (pt) 2017-01-31

Family

ID=42934559

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI1010517A BRPI1010517A2 (pt) 2009-04-09 2010-04-09 métodos para prevenção e/ou tratamento de doenças de armazenamento lisossomal

Country Status (11)

Country Link
US (1) US8940766B2 (enExample)
EP (1) EP2416656B1 (enExample)
JP (1) JP5645918B2 (enExample)
CN (1) CN102625661B (enExample)
AU (1) AU2010233188B2 (enExample)
BR (1) BRPI1010517A2 (enExample)
CA (1) CA2758271C (enExample)
ES (1) ES2564093T3 (enExample)
IL (1) IL215583A (enExample)
NZ (1) NZ595629A (enExample)
WO (1) WO2010118283A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2932982B1 (en) 2005-05-17 2018-10-03 Amicus Therapeutics, Inc. A method for the treatment of pompe disease using 1-deoxynojirimycin and derivatives
US8304429B2 (en) * 2009-04-09 2012-11-06 Amicus Therapeutics, Inc. Methods for preventing and/or treating degenerative disorders of the central nervous system
EP2490533B1 (en) 2009-10-19 2015-09-16 Amicus Therapeutics, Inc. Novel compositions for preventing and/or treating lysosomal storage disorders
RU2015147509A (ru) 2009-10-19 2019-01-14 Амикус Терапьютикс, Инк. Новые композиции для предупреждения и/или лечения дегенеративных расстройств центральной нервной системы
KR20140135222A (ko) 2012-03-07 2014-11-25 아미쿠스 세라퓨틱스, 인코포레이티드 폼페병의 치료를 위한 고농도 알파-글루코시다제 조성물
MX2016010365A (es) * 2014-02-12 2016-11-30 Amicus Therapeutics Inc Derivados de azucares que comprenden restos que contienen azufre, metodos para prepararlos y metodos para emplearlos en el tratamiento de mps iiic.
SI4273241T1 (sl) 2014-09-30 2025-03-31 Amicus Therapeutics, Inc. Zelo močna kislinska alfa-glukozidaza z okrepljenimi ogljikovimi hidrati
KR102510941B1 (ko) 2015-12-30 2023-03-20 아미쿠스 세라퓨틱스, 인코포레이티드 폼페병 치료용의 강화된 산 알파-글루코시다제
NZ786723A (en) 2016-03-30 2025-07-25 Amicus Therapeutics Inc Method for selection of high m6p recombinant proteins
CA3019128A1 (en) 2016-03-30 2017-10-05 Amicus Therapeutics, Inc. Formulations comprising recombinant acid alpha-glucosidase
DK3624831T5 (da) 2017-05-15 2024-09-02 Amicus Therapeutics Inc Rekombinant human sur alfa-glucosidase
WO2020023390A1 (en) 2018-07-25 2020-01-30 Modernatx, Inc. Mrna based enzyme replacement therapy combined with a pharmacological chaperone for the treatment of lysosomal storage disorders

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4407957A (en) 1981-03-13 1983-10-04 Damon Corporation Reversible microencapsulation of a core material
CA2109085C (en) 1991-04-25 2003-03-11 Keith E. Dionne Implantable biocompatible immunoisolatory vehicle for delivery of selected therapeutic products
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
US5569189A (en) 1992-09-28 1996-10-29 Equidyne Systems, Inc. hypodermic jet injector
ES2179831T3 (es) 1992-09-29 2003-02-01 Inhale Therapeutic Syst Liberacion en los pulmones de fragmentos activos de hormona paratiroidiana.
ATE243196T1 (de) * 1994-03-09 2003-07-15 Novo Nordisk As Piperidine und pyrrolidine
FR2718357B1 (fr) 1994-04-06 1997-10-03 Defarges Alain Moreau Perfectionnements apportés à un dispositif d'injection par jet sans aiguille.
US5844102A (en) 1994-07-07 1998-12-01 University Of Maryland Baltimore County Glycohydrolase inhibitors, their preparation and use thereof
US5599302A (en) 1995-01-09 1997-02-04 Medi-Ject Corporation Medical injection system and method, gas spring thereof and launching device using gas spring
US5780014A (en) 1995-04-14 1998-07-14 Inhale Therapeutic Systems Method and apparatus for pulmonary administration of dry powder alpha 1-antitrypsin
US5654007A (en) 1995-06-07 1997-08-05 Inhale Therapeutic Systems Methods and system for processing dispersible fine powders
US20040204379A1 (en) * 2000-06-19 2004-10-14 Cheng Seng H. Combination enzyme replacement, gene therapy and small molecule therapy for lysosomal storage diseases
AU2002306848A1 (en) * 2001-03-23 2002-10-08 Elan Pharmaceuticals, Inc. Methods of treating alzheimer's disease with piperidin derivates
EP1558245A2 (en) 2002-10-28 2005-08-03 Novo Nordisk A/S Use of glycogen phosphorylase inhibitors for treatment of cardiovascular diseases
US7446098B2 (en) 2003-02-18 2008-11-04 Mount Sinai School Of Medicine Of New York University Combination therapy for treating protein deficiencies
US20050137223A1 (en) * 2003-11-12 2005-06-23 Amicus Therapeutics, Inc. Glucoimidazole and polyhydroxycyclohexenyl amine derivatives to treat gaucher disease
KR101402554B1 (ko) * 2006-06-23 2014-06-19 아미쿠스 세라퓨틱스, 인코포레이티드 β-글루코세레브로시다제의 활성 증진에 의한 신경계 장애 치료 방법
WO2008134628A2 (en) * 2007-04-26 2008-11-06 Amicus Therapeutics, Inc. Dosing regimens for the treatment of lysosomal storage diseases using pharmacological chaperones
WO2010048532A1 (en) 2008-10-24 2010-04-29 Amicus Therapeutics, Inc. Multiple compartment dosing model
US8304429B2 (en) * 2009-04-09 2012-11-06 Amicus Therapeutics, Inc. Methods for preventing and/or treating degenerative disorders of the central nervous system

Also Published As

Publication number Publication date
AU2010233188B2 (en) 2015-07-16
US8940766B2 (en) 2015-01-27
EP2416656A4 (en) 2012-09-05
WO2010118283A1 (en) 2010-10-14
CN102625661B (zh) 2015-05-27
EP2416656B1 (en) 2015-12-23
NZ595629A (en) 2013-04-26
IL215583A0 (en) 2011-12-29
JP2012523431A (ja) 2012-10-04
AU2010233188A1 (en) 2011-11-03
EP2416656A1 (en) 2012-02-15
JP5645918B2 (ja) 2014-12-24
CA2758271A1 (en) 2010-10-14
ES2564093T3 (es) 2016-03-17
US20100260740A1 (en) 2010-10-14
IL215583A (en) 2016-09-29
CA2758271C (en) 2018-06-05
CN102625661A (zh) 2012-08-01

Similar Documents

Publication Publication Date Title
BRPI1010517A2 (pt) métodos para prevenção e/ou tratamento de doenças de armazenamento lisossomal
PT2470191E (pt) Métodos e composições para prevenção ou tratamento de doenças oftálmicas
HUE049880T2 (hu) Anyag és eljárások Her-3-mal összefüggõ betegségek kezelésére vagy megelõzésére
IL226049A0 (en) Composition for use in the prevention and/or treatment of skin conditions and skin diseases
BRPI0908026A2 (pt) Métodos para o tratamento de doenças do intestino
BR112014002619A2 (pt) composição farmacêutica e método de tratamento e/ou prevenção de câncer pancreático e combinação farmacêutica
ZA201202596B (en) Compounds for the treatment of dyslipidemia and related diseases
BRPI1008909A2 (pt) métodos e sistema de tratamento de veia
BRPI0921321A2 (pt) métodos para o tratamento de indwcções e tumores
BR112013016535A2 (pt) extratos vegetais para o tratamento e prevenção de infecções
IL207360A0 (en) Methods of diagnosing and treating parp - mediated diseases
EP2155197A4 (en) TREATMENT OF LYSOSOMAL STORAGE DISEASES
GB2496794B (en) Combination pharmaceutical composition and methods of treating functional diseases or conditions of gastrointestinal tract
BRPI1008566A8 (pt) métodos e composições para o diagnóstico e tratamento de câncer
PT2796457T (pt) Genz 112638 para o tratamento de doença de gaucher ou de fabry em terapia de associação
PT2582683T (pt) Tratamento da gota e de hiperuricemia
PT2398902T (pt) Métodos e composições para diagnóstico e tratamento de cancro
EP2627331A4 (en) METHODS OF TREATING HYPERURICEMIA AND RELATED DISEASES
BRPI1015472A2 (pt) métodos para prevenção e/ou tratamento de doenças degenerativas do sistema nervoso central
HRP20181608T1 (hr) Korištenje inhibitora pde7 u liječenju bolesti kretanja
PT2613798E (pt) Utilização de lipase ácida lisossomal para o tratamento da deficiência de lipase ácida lisossomal em doentes
ITTO20110641A1 (it) Composizioni farmaceutiche e metodi di trattamento
HRP20150052T1 (xx) Fungicidni pripravak i postupak za suzbijanje bolesti biljaka
BR112012002265A2 (pt) composições farmacêuticas para o tratamento de câncer e outras doenças ou distúrbios
ZA201105284B (en) Visfatin therapeutic agents for the treatment of acne and other conditions

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL